Comparative Pharmacology
Head-to-head clinical analysis: NUTRACORT versus PSORCON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NUTRACORT versus PSORCON.
NUTRACORT vs PSORCON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid receptor agonist; induces anti-inflammatory proteins and suppresses inflammatory mediators.
Psorcon (diflorasone diacetate) is a corticosteroid that acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins. It inhibits the release of arachidonic acid, thereby decreasing the formation of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
One capsule (200 mg) orally twice daily with meals.
Apply a thin layer to affected skin twice daily. For scalp conditions, use lotion or shampoo as directed.
None Documented
None Documented
Terminal half-life: 2-4 hours (mean 3 hours). Clinically, dosing every 6-8 hours maintains therapeutic levels.
Terminal elimination half-life is approximately 2 hours (range 1.5–3 hours) after topical application; clinical significance: short half-life allows twice-daily dosing.
Renal (primarily as glucuronide and sulfate conjugates, <10% unchanged) and fecal (biliary excretion of metabolites). Approximately 70-80% renal, 20-30% fecal.
Primarily renal (about 70% as unchanged drug and metabolites); biliary/fecal elimination of approximately 30%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid